3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Prostatic Neoplasms
6
Carcinoma, Renal Cell
5
Brain Neoplasms
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Kidney Neoplasms
2
Glioma
2
Glioblastoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Pain
1
Osteosarcoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
pembrolizumab
1
cabozantinib
1
apatinib
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Adenoid Cystic
×
cabozantinib
×
Clear all
NCT03729297
2021-03-12
Cabo ASAP
Radboud University Medical Center
Phase 2
Terminated
25 enrolled